IQ Capital’s Post

🌟 Excited to be attending #ESMOBreast24 in Berlin tomorrow. Looking forward to meeting the experts in emerging biomarkers and treatments in breast cancer. 🔬 Particularly interested in connecting with professionals in this field and discussing digital PCR solutions for ESR1 liquid biopsy in breast cancer monitoring. If you're at the conference and working in these areas, let's connect! 🤝 #BreastCancerResearch #ESMOBreast24 #Droplex #ESR1 #BIOTYPE #LiquidBiopsy

Remember when we posted last week about how important both your detection and concentration methods are for low concentration samples? Liquid biopsies are the perfect example that require the highest performing workflows for detecting cancer mutations such as KRAS. Get the most out of your cancer research samples by combining our ultrasensitive oncology assays with the Ceres NEAT Biopsy Kit. Request our App Notes or this one from Ceres Nanosciences and learn more here: https://lnkd.in/eiv9xThW   #CeresNeat #GTMolecular #KRASdetection #CancerResearch #LiquidBiopsy #PCR #dPCR #digitalPCR #QIAcuity Ceres Nanosciences, Inc. QIAGEN Research use only. Not intended for diagnostic purposes.

Powerful statistics from World Ovarian Cancer Coalition representing an urgent and unmet need in therapeutic innovation. At InnovoTEX, we are using a biomarker driven approach to circumvent resistance to SOC in wt p53 solid tumors, including ovarian cancer. #worldovariancancerday2024

Advancing extracellular vesicle-enabled liquid biopsy for lung cancer detection: in this concise review article, Adeel Khan, Nongyue He at Southeast University and Faisal Raza 费赛 at Shanghai Jiao Tong University explored the potential of EV-based liquid biopsies for lung cancer, highlighting the strengths, weaknesses, and challenges of current EV isolation and analysis techniques for broader clinical application https://lnkd.in/eEhRHctd They noted that EV-based liquid biopsies offer promising opportunities for developing innovative diagnostic and prognostic tools for lung cancer. #extracellularvesicles #exosomes #lungcancer #liquibiopsy #Vesiculab

#ICYMI: In October, we presented new preclinical data at #ENA24 that demonstrate the activity of our DLL3-targeted radioligand therapy in several tumor models, including those with low DLL3 expression levels, supporting its potential to address a range of solid tumors (Poster ENA24-152). #RLT #radioligandtherapy #oncology

Exciting data presented by the Mariana Oncology, a Novartis company, team at the 36th EORTC-NCI-AACR Symposium today! Building upon the data presented at #ESMO2024, which demonstrated a favorable preclinical biodistribution profile, the #ENA2024 results emphasize the activity of our DLL3-targeted radioligand therapy in several tumor models, including those with low DLL3 expression levels. (Poster ENA24-152) The results reinforce the potential of our precise approach to radiopharmaceutical design, in which we apply focused optimization to each component to yield compounds with holistic properties ideal for selective tumor engagement and destruction. #RLT #radioligandtherapy #oncology #drugdevelopment

Researchers at the University of Pittsburgh have developed a novel method to cultivate T cells in the lab, enabling them to live longer and more effectively combat cancer cells. By supplementing the growth medium with dichloroacetate (DCA), T cells become less dependent on glucose and better equipped to utilize other energy sources. In mouse models of melanoma, these DCA-cultured T cells demonstrated enhanced tumor control and prolonged survival. This advancement holds promise for improving the efficacy of T cell-based cancer immunotherapies. Read the full story here:https://lnkd.in/ddu8nbEm

Book chapter on "Challenges in the development of nanobiosensors in the diagnosis of cancer" Abstract: Recent developments in the nanobiosensors field offer enormous advantages, such as high sensitivity, reproducibility, and fast analysis of biomolecules making this analytical tool very promising for this purpose. This chapter aims to provide a summary of circulatory biomarkers of cancer and current biosensor based approaches for early detection and diagnosis of cancer. https://lnkd.in/gQxVDm8E.

The role of cancer-associated fibroblasts (CAFs) in non-small cell lung cancer (NSCLC) tumor microenvironment. Key Points: CAFs contribute to drug resistance, cancer stem cell regulation, and immune suppression. Targeting CAFs may improve NSCLC treatment outcomes. Heterogeneity among CAFs necessitates the identification of specific markers for effective therapies. Various signaling pathways (e.g., TGF-β, IL-6) are involved in CAF-mediated tumor progression and resistance. This article concludes that "CAF-targeted therapies hold potential for enhancing NSCLC treatment efficacy." #cancer #cancerresearch #CAF cells #Tumor microenvironment #NSCLC

September is #ProstateCancerAwarenessMonth. We are committed to advancing clinical care for patients with prostate cancer, and earlier this year, we introduced p-MSI, our MSI-High predictive algorithm specifically for this patient population. In prostate cancer, MSI is uncommon and is not typically tested for, but has been reported at ~2-3% prevalence1. Learn more: https://tempus.co/47wvOE7 1. Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5(4):471-478.